INT37012

From wiki-pain
Revision as of 09:53, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.33
First Reported 1984
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 4.83
Pain Relevance 0.70

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Clcn1) transmembrane transport (Clcn1)
Anatomy Link Frequency
brain 1
chest 1
CLC 1
mere 1
Clcn1 (Mus musculus)
Pain Link Frequency Relevance Heat
Central nervous system 5 97.40 Very High Very High Very High
Analgesic 1 91.32 High High
opiate 1 90.88 High High
Pain 5 90.64 High High
cINOD 1 88.32 High High
tolerance 1 75.68 Quite High
ketamine 6 73.24 Quite High
Paracetamol 2 50.00 Quite Low
imagery 5 25.00 Low Low
Migraine 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Adverse Drug Reaction 130 100.00 Very High Very High Very High
Osteogenic Sarcomas 2 96.32 Very High Very High Very High
Brain Tumor 26 94.24 High High
Myotonia Congenita 7 93.60 High High
Disease 31 90.96 High High
Myalgia 1 90.64 High High
Bacterial Respiratory Disease 1 88.04 High High
Cancer 81 87.56 High High
Hypertrophy 1 84.36 Quite High
Pain 4 83.40 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Generation of CLCN1-luc Construct
CLCN1 Binding (Generation) of
1) Confidence 0.33 Published 2010 Journal Current Chemical Genomics Section Body Doc Link PMC2874217 Disease Relevance 0.23 Pain Relevance 0
The factors associated most strongly with ADR were advanced age and use of multiple medications.
ADR Binding (associated) of associated with adverse drug reaction
2) Confidence 0.30 Published 2006 Journal Rev Clin Esp Section Abstract Doc Link 16831381 Disease Relevance 1.23 Pain Relevance 0.32
For the physician, the task of recognizing an adverse drug reaction (ADR) is an extremely complex one.
ADR Binding (recognizing) of associated with adverse drug reaction
3) Confidence 0.30 Published 1984 Journal Soc Sci Med Section Abstract Doc Link 6701562 Disease Relevance 0.53 Pain Relevance 0.08
Moreover, the mere fact of recognizing an ADR does not mean that it can be prevented.
ADR Binding (recognizing) of in mere associated with adverse drug reaction
4) Confidence 0.30 Published 1984 Journal Soc Sci Med Section Abstract Doc Link 6701562 Disease Relevance 0.49 Pain Relevance 0.05
In-depth semi-structured interviews were conducted from September 2007 to December 2007 with NHP consumers who had experienced a self-identified suspected ADR associated with use of an NHP within the past 5 years.
ADR Binding (associated) of
5) Confidence 0.16 Published 2010 Journal BMC Complement Altern Med Section Body Doc Link PMC2847952 Disease Relevance 0.13 Pain Relevance 0
We were unable to explore the decision-making processes of individuals who experienced suspected ADR(s) while taking NHPs, but who had decided that these products were not associated with their ADR(s).
ADR Binding (associated) of
6) Confidence 0.16 Published 2010 Journal BMC Complement Altern Med Section Body Doc Link PMC2847952 Disease Relevance 0.07 Pain Relevance 0
Therefore, in the chemotherapeutic trials conducted here, ADR conjugates were particularly good candidates for evaluation because free ADR is excluded from the brain by Pgp1 efflux activity and because ADR is completely ineffective in treating brain tumors [92] because of hindrance by the BBB.
ADR Binding (conjugates) of in brain associated with brain tumor
7) Confidence 0.13 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2424243 Disease Relevance 0.90 Pain Relevance 0
Conjugation of ADR [(8S,10S)-10-(4-amino-5-hydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxy-acetyl)-1-methoxy-7,8,9,10 tetrahydrotetracene-5,12-dione] to p97 was achieved by cross-linking p97-N-succinimidyl S-acetylthioacetate (p97-SATA) and ADR-succinimidyl 4-[N-maleimidomethyl]-cyclohexane-1-carboxylate (ADR-SMCC) derivatives.
ADR Binding (Conjugation) of
8) Confidence 0.13 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2424243 Disease Relevance 0 Pain Relevance 0.04
The following ADR were significantly associated with IV-NAC administration: vomiting (p = .001), flushing (p < .001), rash (p < .001), pruritus (p < .001), chest pain (p = .001), bronchospasm (p = .03), coughing (p = .01), headache (p = .001), dizziness (p < .001), convulsion (p = .03), and hypotension (p = .001).
ADR Binding (associated) of in chest
9) Confidence 0.10 Published 2010 Journal Hum Exp Toxicol Section Body Doc Link 20071472 Disease Relevance 0.06 Pain Relevance 0
The good results obtained with the postoperative ADR-CDDP association led us to undertake a pilot study between 1982 and 1984, using ADR-CDDP as preoperative chemotherapy.
ADR-CDDP Binding (association) of
10) Confidence 0.02 Published 1986 Journal Bull Cancer Section Abstract Doc Link 3463371 Disease Relevance 0.43 Pain Relevance 0.11
We noted that four newly identified dominant mutations clustered in exon 8, which codes for a highly conserved region of predicted interaction between the CLC-1 monomers.
CLC-1 Binding (interaction) of in CLC
11) Confidence 0.01 Published 2007 Journal Brain Section Abstract Doc Link 17932099 Disease Relevance 0.75 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox